According to the report, the Europe Perfusion Systems Market Size is valued at USD 0.33 billion in 2020 and expected to grow at a CAGR of 3.2%, to reach USD 0.39 billion by 2025 during the forecast period 2020-2025.
Perfusion is the path of fluid from the circulatory system or lymphatic system to an organ or a tissue, generally denoting to the delivery of blood to a capillary bed in tissue. Cardiac perfusion systems were used for some time to replace the functions of the heart in cardiac surgeries. The introduction of technologically advanced products for the purpose of enhanced efficiency and cost-effectiveness is expected to serve this market with lucrative opportunities
The crucial factor driving the growth of this market is increasing number of cardiac surgeries. .Growing prevalence of cardiac and lung diseases in developed as well as developing further propels the growth of this market. Though, inadequate number of well-trained surgeons in emerging nations, unstable reimbursement policies, and stiff competition from local players with low-cost products are hinders the growth of this market.
Europe Perfusion Systems Market has been segmented and sub-segmented into the following categories
On the basis of type, the bioreactor perfusion systems segment holds the major share of the perfusion systems market in 2018 and is projected to record the highest CAGR during the forecast period.
On the basis of region, Europe had a low CAGR during the forecast period. The reasons for the same might be government policies.
Prominent Companies leading the Europe Perfusion Systems Market Profiled in the Report are Getinge AB, Medtronic plc, LivaNova PLC, Terumo Corporation, XENIOS AG, Repligen Corporation, Spectrum Laboratories, Inc, Merck KGaA, Harvard Bioscience, Inc, ALA Scientific Instruments, Inc.,
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Component
5.1.1 Heart-lung Machines
5.1.2 Perfusion Pumps
5.1.3 Oxygenators
5.1.4 Monitoring Systems
5.1.5 Cannulas
5.1.6 Other Components
5.1.7 Y-o-Y Growth Analysis, By Component
5.1.8 Market Attractiveness Analysis, By Component
5.1.9 Market Share Analysis, By Component
5.2 Type
5.2.1 Bioreactor Perfusion Systems
5.2.2 Microfluidic Perfusion Systems
5.2.3 Gravity/Pressure-driven Perfusion Systems
5.2.4 Small-mammal Organ Perfusion Systems
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Technique
5.3.1 Hypothermic Machine Perfusion Systems
5.3.2 Normothermic Machine Perfusion Systems
5.3.4 Y-o-Y Growth Analysis, By Technique
5.3.5 Market Attractiveness Analysis, By Technique
5.3.6 Market Share Analysis, By Technique
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Component
6.1.3.3 By Type
6.1.3.4 By Technique
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Component
6.1.4.3 By Type
6.1.4.4 By Technique
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Component
6.1.5.3 By Type
6.1.5.4 By Technique
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 AB (Sweden)
8.1.1 Overview
8.1.2 Component Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Medtronic plc (Ireland),
8.3 LivaNova PLC (U.K.)
8.4 Terumo Corporation (Japan)
8.5 XENIOS AG (Germany)
8.6 ALA Scientific Instruments, Inc. (U.S.)
8.7 Repligen Corporation (U.S.)
8.8 Spectrum Laboratories, Inc. (U.S.)
8.9 Merck KGaA (Germany)
8.10 Harvard Bioscience, Inc. (U.S.)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
